Please assess the completion status of the following clinical trial:

Trial Title: Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Histologically proven cutaneous melanoma.~Patient's melanoma must be in one of the following AJCC stages :~only primary tumor : T3b-T4, N0, M0. regional lymph node metastasis and/or in-transit metastasis, no distant metastasis (any T, N1-N3, M0) that has been removed.~Any distant metastasis that has been removed (M1) HLA-A2 positive. Patients with previous regional metastatic disease must have one of their resected lesions analyzed by RT-PCR to determine expression of genes MAGE-1, MAGE-3, MAGE-4, MAGE-10, MAGE-C2, NA17, Tyrosinase or NY-ESO-1. However, expression of these genes by the tumor is not required to enter the study.~Absence of detectable melanoma lesions. WHO/ECOG performance status of 1 or less (Karnofsky scale ≥ 70%).~The following laboratory results:~Hemoglobin ≥ 10 g/dl; Neutrophils ≥ 1,500/µl; Lymphocytes ≥ 700/µl; Platelets ≥ 100,000/µl; Serum creatinin ≤ 2.0 mg/dl; Serum bilirubin ≤ 2.0 mg/dl; LDH within normal institutional limits.~Age \> 18 years. Able to give written informed consent.~Exclusion Criteria:~Clinically significant heart disease (NYHA Class III or IV). Other serious illnesses, e.g. serious infections requiring antibiotics, bleeding disorders, a second active malignancy, except basal cell carcinoma or in situ carcinoma of the uterine cervix.~Active immunodeficiency disease or autoimmune disease. Positive serology for HIV (human immunodeficiency virus) or HCV (hepatitis C virus). Serum hepatitis B antigen (HBsAg) must be negative.~More than one line of previous chemotherapy, or immunotherapy for the melanoma. Previous vaccination with one of the antigen present in the vaccine. Treatment with steroids or major immunosuppressive drugs within 4 weeks before study entry. Topical or inhalational steroids are permitted.~Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.~Pregnancy or lactation. Women of childbearing potential not using a medically acceptable means of contraception.~Psychiatric or addictive disorders that may compromise the ability to give informed consent.~Lack of availability of the patient for immunological and clinical follow-up assessment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): The eight HLA-A2 peptides
- Group B (Type: EXPERIMENTAL): The eight HLA-A2 peptides + immunological adjuvant Montanide ISA51
- Group C (Type: EXPERIMENTAL): the eight peptides HLA-A2 + IMP321
- Group D (Type: EXPERIMENTAL): The eight HLA-A2 peptides + the 2 immunological adjuvants (Montanides ISA 51 and IMP321)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval